Market & News

Dear Members,

Alkem Laboratories Limited

Your Directors are pleased to present their 52^nd Annual Report on the business and operations together with the Audited

Financial Statements of the Company for financial year ended 31 March, 2026. Consolidated performance of the Company and its subsidiaries has been referred to, wherever required

FINANCIAL PERFORMANCE

	Standalone	Consolidated
Particulars	Year ended 31 March, 2026	Year ended 31 March, 2025	Year ended 31 March, 2026	Year ended 31 March, 2025
Revenue from continuing operations	96,639.1	88,134.4	147,122.7	129,645.2
Other Income	5,551.7	5,070.6	5,833.5	4,937.4
Total Income from continuing operations	102,190.8	93,205.0	152,956.2	134,582.6
Profit before Exceptional items, Interest,	29,795.6	26,632.6	35,885.6	30,058.9
Depreciation and Tax
Less: Exceptional items	1,430.9	-	1,748.3	-
Less: Interest	572.9	761.1	1,607.8	1,217.0
Less: Depreciation	2,565.6	2,836.1	3,820.6	3,571.6
Profit before Tax from continuing operations	25,226.2	23,035.4	28,708.9	25,270.3
Less: Provision for Taxation (net) from continuing operations	3,375.0	2,138.2	5,177.6	3,110.3
Less: Share in loss after tax of associates (net)	-	-	19.7	6.2
Profit after Tax and before Non-Controlling	21,851.2	20,897.2	23,511.6	22,153.8
Interest from continuing operations
Less: Non-Controlling Interest	-	-	493.6	499.0
Profit for the year from continuing operations	21,851.2	20,897.2	23,018.0	21,654.8
Profit before Tax from discontinued operations	1,490.5	2,938.5	-	-
Tax expense of discontinued operations	520.8	1,026.8	-	-
Profit from discontinued operations (after Tax)	969.7	1,911.7	-	-
Profit for the year	22,820.9	22,808.9	23,018.0	21,654.8
Other Comprehensive Income	46.2	(115.0)	1,823.8	207.5
Other Comprehensive Income attributable to	-	-	14.1	(10.3)
Non-Controlling Interest
Total Comprehensive Income attributable to owners of the Company	22,867.1	22,693.9	24,841.8	21,862.3
Balance of other Equity as of 01.04.2025	122,979.2	105,307.0	119,609.6	102,881.5
Dividend on Equity Shares	(6,097.8)	(5,021.7)	(6,097.8)	(5,021.7)
Recognition of put option liability during the year	-	-	(370.3)	(278.6)
Employee compensation expense for the year	-	-	48.7	166.1
Employee stock option exercised	-	-	(42.8)	-
Changes in proportion held by non-controlling interest	-	-	(27.3)	-
Balance of other Equity as of 31.03.2026	139,748.5	122,979.2	137,961.9	119,609.6

OVERVIEW OF FINANCIAL PERFORMANCE

During financial year ended 31 March, 2026, the Company's total revenue including other income was C 102,190.8 Million on Standalone basis as against C 93,205.0 Million achieved in the previous year, registering a growth of 9.6 %.

The export turnover of the Company during financial year 2025-26 was C 26,405 Million as against C 24,908.3 Million achieved in the previous year, registering a growth of 6.0 %.

During financial year ended 31 March, 2026, the Company and its subsidiaries achieved a total revenue including other income of C 152,956.2 Million on Consolidated basis, as against a turnover of C 134,582.6 Million achieved in the previous year, registering a growth of 13.7 %.

During financial year ended 31 March, 2026, Standalone Profit before exceptional items, interest, depreciation and tax from continuing operations increased by 11.9 % at C 29,795.6 Million as against C 26,632.6 Million in the previous year, whereas Consolidated Profit before exceptional items, interest, depreciation and tax increased by 19.4 % at C 35,885.6 Million as against C 30,058.9 Million in the previous year. As a result, Standalone Profit before tax increased by 9.5 % over the previous year to C 25,226.2 Million and Consolidated Profit before tax was C 28,708.9 Million, which grew by 13.6 % over the previous year.

The Standalone Net Profit after tax for financial year ended 31 March, 2026 increased by 4.6 % to C 21,851.2 Million over the previous year while the Consolidated Net Profit after tax increased by 6.3% over the previous year to C 23,018.0 Million.

DIVIDEND

During financial year 2025-26, the Board of Directors on 13 February, 2026, declared and paid an interim dividend of C 43/- (Rupees Forty Three only) per equity share of C 2/- (Rupees Two only) each, being 2150% of paid up share capital of the Company. In addition, your Directors are pleased to recommend payment of C 10/- (Rupees Ten only) per equity share of C 2/- (Rupees Two only) each as final dividend for financial year 2025-26, for the approval of the Members at the ensuing Annual General Meeting (AGM) of the Company. If approved, the total dividend (interim and final) for financial year 2025-26 will be C 53/- (Rupees Fifty Three only) per equity share of C 2/- (Rupees Two only) each as against the total dividend of C 45/- (Rupees Forty Five only) per equity share of C 2/- (Rupees Two only) each paid for the previous financial year.

In compliance with the requirement of Regulation 43A of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "SEBI LODR Regulations"), the Company has formulated its Dividend Distribution Policy, which is available on the Company's website at https://admin.alkemlabs.com/uploads/977928327_ Dividend_distribution_policy_6b026313dc.pdf

The said Policy is also annexed to this Report as Annexure A.

TRANSFER TO RESERVES

The Board does not propose to transfer any amount to the General Reserve for financial year 2025-26.

SHARE CAPITAL

The paid up equity share capital of the Company as on 31 March, 2026 was C 239.1 Million. The Company has neither issued shares with differential rights as to dividend, voting or otherwise nor issued shares to the Employees or Directors of the Company, under any scheme (including sweat equity shares).

DEPOSITS

The Company has not accepted any deposits from the public/ members during the year under review and accordingly no amount on account of principal or interest on public deposits was outstanding as on 31 March, 2026.

SUBSIDIARIES

As on 31 March, 2026, the Company has a total of 33 subsidiaries and 2 associate companies within the meaning of Sections 2(87) and 2(6) of the Companies Act, 2013 (hereinafter referred to as "the Act") respectively. The Company does not have any joint venture company(ies).

During the year under review: x Acquired 100% stake of M/s. Bombay Ortho Industries Private Limited through M/s. Alkem Medtech Private Limited, thereby making it a Wholly-owned step-down subsidiary of the Company w.e.f. 16 April, 2025. Subsequently, the name of M/s. Bombay Ortho Industries Private Limited was changed to ‘Alkem MedTech Ortho Private Limited' w.e.f. 9 June, 2025; x Acquired 100% stake of M/s. Adroit Biomed Limited, thereby making it a Wholly-owned subsidiary of the Company w.e.f. 23 April, 2025; x M/s. Alkem Pharmaceuticals Scientific Office FZ-LLC was incorporated as a Wholly-owned subsidiary of the Company in Dubai, on 04 February, 2026; x M/s. Alkem Pharma Trading FZCO was incorporated as a Wholly-owned subsidiary of the Company in Dubai, on 27 March, 2026. and none of the companies ceased to be a subsidiary of the Company.

Pursuant to the first proviso to Section 129(3) of the Act and Rule 5 and Rule 8(1) of the Companies (Accounts) Rules, 2014, the salient features of financial statements, performance and financial position of each subsidiary is given in Form AOC-1 as Annexure B to this Report.

The Audited Financial Statements of the subsidiaries are available on the Company's website at https://www. alkemlabs.com/investors/subsidiary-accounts pursuant to Section 136 of the Act.

SCHEME OF MERGER

The Board of Directors of the Company has at its meeting held on 13 February, 2026 approved the amalgamation of Adroit Biomed Limited ("Transferor Company"), a wholly-owned subsidiary of the Company with and into the Company by way of a scheme of arrangement pursuant to the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (including the rules thereunder) ("Scheme"), and in compliance with the provisions of the Income Tax Act.

The Scheme is, inter alia, subject to the sanction of the Mumbai bench of the National Company Law Tribunal ("NCLT") and requisite approvals of the shareholders and/ or creditors of the Company, if so directed by the NCLT, and subject to compliance with applicable laws or other approvals, if required.

MANAGEMENT DISCUSSION AND ANALYSIS

A detailed report on the Management Discussion and Analysis is provided as a separate section forming part of this Report.

CORPORATE GOVERNANCE

In compliance with Regulation 34 read with Schedule V of the SEBI LODR Regulations, a Report on Corporate Governance for the year under review is provided as a separate section along with a certificate from the Statutory Auditors conforming the Company's compliance with the conditions of Corporate Governance, forming part of this Report.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT

In compliance with Regulation 34 of SEBI LODR Regulations, the Business Responsibility and Sustainability Report, describing the initiatives taken by the Company from an environmental, social and governance perspective, is provided as a separate section forming part of this Report.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Company undertakes CSR activities in accordance with the Company's CSR Policy. The CSR programme aims to address the immediate and long term needs of the community and focus on where the major impact on marginalized sections of the society can be made. The Company's CSR strategy involves a multi-sectoral inclusive approach to focus on community needs. It strives to improve the well-being of communities by focusing on key thematic areas of healthcare, education, rural development, environment and sports. The Company implements these activities directly or through reliable partnerships with various NGOs. During financial year 2025-26, the Company has addressed the requirements of local communities in the vicinity of its head office, manufacturing facilities and R&D centers through focused projects in the said thematic areas.

Details about the Company's CSR Policy and initiatives undertaken by the Company during financial year 2025-26 are outlined in the Report on CSR activities annexed to this Report as Annexure C.

The CSR Policy is posted on Company's website: https:// admin.alkemlabs.com/uploads/csr_policy_e0e5ec8d61.pdf

DIRECTORS AND KEY MANAGERIAL PERSONNEL

Appointments:

The details of the appointments during the year under review are as follows:

Appointment of Mr. Ranjal Laxmana Shenoy as an Independent Director of the Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high standards of integrity possessed by Mr. Ranjal Laxmana Shenoy (DIN: 00074761), the Board of Directors of the Company based on recommendation of the Nomination and Remuneration Committee and subject to approval of the Members of the Company, approved the appointment of Mr. Ranjal Laxmana Shenoy (DIN: 00074761) as an Additional Director designated as an Independent Director of the Company.

Thereafter, the Members of the Company through Postal Ballot on 12 July,2025 approved the said appointment of Mr. Ranjal Laxmana Shenoy as an Independent Director of the Company, not liable to retire by rotation, for a term of 5 (five) consecutive years w.e.f. 13 July, 2025 upto 12 July, 2030.

Appointment of Ms. Neela Bhattacherjee as an Independent Director of the Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high standards of integrity possessed by Ms. Neela Bhattacherjee (DIN: 01912483), the Board of Directors of the Company based on recommendation of the Nomination and Remuneration Committee and subject to approval of the Members of the Company, approved the appointment of Ms. Neela Bhattacherjee (DIN: 01912483) as an Additional Director designated as an Independent Director of the Company.

Thereafter, the Members of the Company through Postal Ballot on 12 July, 2025 approved the said appointment of Ms. Neela Bhattacherjee as an Independent Director of the Company, not liable to retire by rotation, for a term of 5 (five) consecutive years w.e.f. 13 July, 2025 upto 12 July, 2030.

Appointment of Mr. Diwakar Gupta as an Independent Director of the Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high standards of integrity possessed by Mr. Diwakar Gupta (DIN: 01274552), the Board of Directors of the Company based on recommendation of the Nomination and Remuneration

Committee and subject to approval of the Members of the Company, approved the appointment of Mr. Diwakar Gupta (DIN: 01274552) as an Additional Director designated as an Independent Director of the Company.

The Members of the Company through Postal Ballot on 02 August, 2025 approved the said appointment of Mr. Diwakar Gupta as an Independent Director of the Company, not liable to retire by rotation, for a term of 5 (five) consecutive years w.e.f. 13 July, 2025 upto 12 July, 2030.

Re-appointment:

Re-appointment of Mrs. Madhurima Singh, Executive Director of the Company.

The Board of Directors of the Company based on the recommendation of the Nomination and Remuneration Committee and Audit Committee and pursuant to the relevant provisions of SEBI LODR Regulations, Sections 196, 197 and 198 read with Schedule V and other applicable provisions of the Act, the Articles of Association of the Company and considering her contribution towards the growth of the Company, approved the re-appointment of Mrs. Madhurima Singh as an Executive Director of the Company for a term of 5 (five) consecutive years commencing from 20 December, 2026 upto 19 December, 2031 subject to the approval of the Members of the Company.

Completion of tenure

Tenure Completion

Mr. Arun Kumar Purwar, Ms. Sangeeta Singh and Ms. Sudha Ravi retired from the Board of Directors of the Company after the close of business hours on 12 July, 2025, upon completion of their second term as Independent Directors of the Company. The Directors place on record their appreciation on the contribution made by the above Directors in the growth of the Company during their tenure.

Directors liable to retire by rotation

Mr. Sandeep Singh (DIN: 01277984) and Mr. Sarvesh Singh (DIN: 01278229) are liable to retire by rotation at the ensuing AGM of the Company pursuant to the provisions of Section 152 of the Act read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of the Company and being eligible they have offered themselves for re-appointment, on the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company.

Particulars in pursuance of Regulation 36 of the SEBI LODR Regulations read with Secretarial Standard – 2 on General Meetings relating to Mr. Sandeep Singh and Mr. Sarvesh Singh are given in the Notice of AGM.

Key Managerial Personnel

In accordance with the provisions of Section 203 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the following are the Key Managerial Personnel of the Company as on 31 March, 2026: x Mr. Sandeep Singh - Managing Director; x Dr. Vikas Gupta - Chief Executive Officer (upto 30 June, 2026); x Mr. Nitin Agrawal - President and Chief Financial Officer; and x Mr. Manish Narang, President - Legal, Company Secretary and Compliance Office

Resignation

Dr. Vikas Gupta Chief Executive Officer and Key managerial personnel of the Company, resigned w.e.f. 30 June, 2026 to pursue new professional opportunities. The Directors placed on record appreciation for the valuable contribution made by Dr. Vikas Gupta during his tenure as a Chief Executive Officer and Key managerial personnel in the Company.

Independent Directors

The Independent Directors hold office for a term of 5 (five) years and are not liable to retire by rotation. The Independent Directors of the Company fulfill the conditions specified in the Act and SEBI LODR Regulations and are independent of the management.

Declaration of independence from Independent Directors

The Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence as prescribed under the provisions of the Act, read with the schedules and rules issued thereunder, as well as Regulation 16(1)(b) of the SEBI LODR Regulations (including any statutory modification(s) or re-enactment(s) thereof for the time being in force). In terms of Regulation 25(8) of the SEBI LODR Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

The terms and conditions of appointment of the Independent Directors are posted on Company's website: https:// admin.alkemlabs.com/uploads/Terms_of_appointment_ Independent_Directors_2a82f9dd72.pdf

Familiarisation Programme

In compliance with the requirements of SEBI LODR Regulations, the Company has put in place a framework for Directors' Familiarisation Programme to familiarize them with their roles, rights and responsibilities as Directors, the working of the Company, nature of the industry in which the Company operates, business model, etc. The details of the Familiarisation Programme conducted during financial year under review are explained in the Corporate Governance

Report. The same is also available on the Company's website at https://www.alkemlabs.com/investors/details-familiarization-program .

Annual Evaluation of Board's Performance

The details of the annual evaluation of the Individual Directors, Board as a whole and all the Committees of the Board have been provided in the Corporate Governance Report, which forms part of this Report.

The Independent Directors, at a separate meeting held on 26 March, 2026 evaluated performance of Non-Independent Directors, performance of the Board as a whole and performance of the Chairperson of the Company.

The evaluation of the Independent Directors was carried out by the entire Board of Directors without the participation of the respective Independent Director.

The Company follows a policy for selection and appointment of Directors, Senior Management and their remuneration, which is available on the Company's website at https://admin. alkemlabs.com/uploads/1378936118_Nomination_and_ Remuneration_Policy_modified_27052016_307d64b304. pdf. The said Policy is annexed to this Report as Annexure D.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

The disclosure pertaining to remuneration and other details as required under Section 197(12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is annexed to this Report as Annexure E.

Further, a statement showing the names and other particulars of top ten employees in terms of remuneration drawn and of employees drawing remuneration in excess of the limits required under Section 197(12) of the Act read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms part of this Report. However, in terms of first proviso to Section 136(1) of the Act, the Annual Report and Annual Financial Statements are being sent by email to the Members and others entitled thereto, excluding the aforesaid information. The said information shall be provided electronically to any Member on a written request to the Company Secretary to obtain a copy of the same.

NUMBER OF MEETINGS OF THE BOARD

The Board of Directors met 7 (seven) times during financial year 2025-26. The details of the Board meetings and the attendance of Directors thereat are provided in the Corporate Governance Report, which forms part of this Report.

COMMITTEES OF THE BOARD

Audit Committee

As on 01 April, 2025, the Audit Committee comprised of Mr. Arun Kumar Purwar as Chairperson and Mr. Sandeep Singh, Mr. Mritunjay Kumar Singh, Ms. Sangeeta Singh, Mr. Narendra Kumar Aneja and Ms. Sudha Ravi as Members.

Thereafter, the Board at its meeting held on 18 June, 2025, reconstituted the Audit Committee with effect from 13 July, 2025, comprising of Mr. Narendra Kumar Aneja as Chairperson and Mr. Sandeep Singh, Mr. Mritunjay Kumar Singh, Mr. R. L. Shenoy, Mr. Rajeev Kher and Mr. Diwakar Gupta as Members.

The brief terms of reference of the Audit Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Nomination and Remuneration Committee

As on 01 April, 2025, the Nomination and Remuneration Committee comprised of Mr. Arun Kumar Purwar as Chairperson and Mr. Basudeo N. Singh, Ms. Sudha Ravi and Mr. Narendra Kumar Aneja as Members.

Thereafter, the Board at its meeting held on 18 June, 2025 reconstituted the Nomination and Remuneration Committee with effect from 13 July, 2025, comprising of Mr. R. L. Shenoy as Chairperson and Mr. Basudeo N. Singh, Mr. Sujjain Talwar, and Ms. Neela Bhattacherjee as Members.

The brief terms of reference of the Nomination and Remuneration Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Corporate Social Responsibility and Sustainability Committee

As on 01 April, 2025, the Corporate Social Responsibility and Sustainability Committee comprised of Mrs. Madhurima Singh as Chairperson and Mr. Sandeep Singh, Mr. Srinivas Singh, Ms. Sangeeta Singh and Ms. Sudha Ravi as Members.

Thereafter, the Board at its meeting held on 18 June, 2025 reconstituted the Corporate Social Responsibility and Sustainability Committee with effect from 13 July, 2025, comprising of Mrs. Madhurima Singh as Chairperson and Mr. Srinivas Singh, Mr. Sarvesh Singh, Mr. Narendra Kumar Aneja and Mr. Rajeev Kher as Members.

The brief terms of reference of the Corporate Social Responsibility and Sustainability Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee comprises of Mr. Sujjain Talwar as Chairperson and Mr. Mritunjay Kumar Singh, Mrs. Madhurima Singh and Mr. Srinivas Singh as Members.

The brief terms of reference of the Stakeholders' Relationship Committee and the particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

Risk Management Committee

As on 01 April, 2025, the Risk Management Committee comprised of Mr. Mritunjay Kumar Singh as Chairperson and Mr. Sandeep Singh, Mr. Srinivas Singh, Ms. Sudha Ravi, Mr. Narendra Kumar Aneja and Mr. Sujjain Talwar as Members.

Thereafter, the Board at its meeting held on 18 June, 2025 reconstituted the Risk Management Committee with effect from 13 July, 2025, comprising of Mr. Mritunjay Kumar Singh as Chairperson and Mr. Sandeep Singh, Mr. Srinivas Singh, Ms. Neela Bhattacherjee, Mr. Diwakar Gupta and Mr. R. L. Shenoy as Members.

The brief terms of reference of the Risk Management Committee and the particulars of meeting held and attendance thereat are mentioned in the Corporate Governance Report which forms part of this Report.

RISK MANAGEMENT

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company has a Board approved Risk Management Policy. The Board of Directors has constituted a Risk Management Committee which is delegated with the responsibility of overseeing various strategic, operational and financial risks that the organization faces, along with assessment of risks, their management and mitigation procedures. A detailed analysis of the business risks and opportunities is given under Management Discussion and Analysis Report forming part of this Report.

DIRECTORS' RESPONSIBILITY STATEMENT

To the best of their knowledge and belief, your Directors confirm that:

(a) in the preparation of the annual accounts for financial year ended 31 March, 2026, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;

(b) they have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31 March, 2026 and of the profit of the Company for the year ended on that date;

(c) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(d) they have prepared the annual financial statements on a going concern basis;

(e) they have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and operating effectively; and

(f) they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

SECRETARIAL STANDARDS

The Company has devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India and that such systems are adequate and operating effectively.

AUDITORS AND AUDITORS' REPORT

Statutory Auditors

Pursuant to the provisions of Section 139 of the Act and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), M/s. Deloitte Haskins & Sells LLP (Firm Registration No. 117366W/W-100018), Chartered Accountants, the Statutory Auditors of the Company, were appointed pursuant to the resolution passed by the Shareholders at the 50^th AGM of the Company held on 30 August, 2024, for a term of 5 (five) consecutive years from the conclusion of 50^th AGM of the Company until the conclusion of the 55^th AGM to be held in year 2029.

M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, the Statutory Auditors of the Company have confirmed that they are not disqualified from continuing as the Auditors of the Company for financial year 2026-27.

The Auditors' Report for financial year ended 31 March, 2026, is an unmodified one. However, pursuant to CARO report, following adverse remark stated in the Auditor's report:

Delay in respect of remittance of Provident Fund and Profession tax: The delay in remittance of Provident Fund ("PF") is attributable to the earlier process of initiating PF settlements only after receipt of the completed Full & Final (F&F) Clearance Form. To address this, the process has been revised with effect from January 2026, whereby PF remittances have been initiated immediately upon an employee's separation from the Company. This has strengthened statutory compliance, mitigated the risk of interest and penal liabilities, and ensured timely remittance of dues going forward.There has been no delay in respect of remittance of Profession tax.

Cost Auditor

The Company is required to maintain cost records for certain products as specified by the Central Government under Section 148(1) of the Act and accordingly such accounts and records are made and maintained in the prescribed manner.

Pursuant to the provisions of Section 148 of the Act and the rules made thereunder read with notifications/ circulars issued by the Ministry of Corporate Affairs from time-to-time and as per the recommendation of the Audit Committee, the Board of Directors at its meeting held on 29 May, 2025, had re-appointed Mr. Suresh D. Shenoy, Cost Accountant (Membership No. 8318), as the Cost Auditor of the Company for financial year 2025-26 to conduct the audit of the cost records of the Company. A resolution for ratification of the fees payable to the Cost Auditor is included in the Notice of AGM for seeking approval of Members. The Cost Audit Report will be filed within the period stipulated under the Act.

Secretarial Auditors

Pursuant to the provisions of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. Manish Ghia & Associates, Practicing Company Secretaries, (Membership No. F6252, COP No. 3531) to conduct the Secretarial Audit of the Company for a term of 5 (five) consecutive years to hold office w.e.f. 01 April, 2025 upto 31 March, 2030, on such fees as may be decided by the Board of Directors of the Company and the Secretarial Auditors. The said appointment was then approved by the Shareholders at the 51^st Annual General Meeting of the Company held on 25 August, 2025.

The Secretarial Audit Report received from M/s. Manish Ghia & Associates, Secretarial Auditors of the Company, for financial year ended 31 March, 2026 is annexed to this Report as Annexure F. The said Report does not contain any qualification, reservation or adverse remark.

ANNUAL RETURN

The Annual Return of the Company in prescribed Form MGT-7 is available on the website of the Company at https://www. alkemlabs.com/investors/annual-returns

RELATED PARTY TRANSACTIONS

All the Related Party Transactions entered into during financial year 2025-26 by the Company, were at arm's length basis and in compliance with the applicable provisions of the Act and the SEBI LODR Regulations and are in conformity with the Company's Policy on Related Party Transactions.

The disclosure of material related party transactions entered into by the Company during financial year 2025-26, as required under Section 134(3)(h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules, 2014 in Form AOC-2 is annexed to this Report as Annexure G. The

Policy on Related Party Transactions as approved by the Board of Directors is posted on the Company's website at https://admin.alkemlabs.com/uploads/Related_Party_ Transactions_Policy_1e79a77a4a.pdf

PARTICULARS OF LOANS/ GUARANTEES GIVEN/ INVESTMENTS MADE AND SECURITIES PROVIDED

The particulars of loans, guarantees, investments and securities provided covered under the provisions of Section 186 of the Act have been disclosed in the notes to the financial statements forming part of the Annual Report.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

Pursuant to the provisions of Section 177(9) of the Act, the Board of Directors of the Company have framed the Vigil Mechanism / Whistle Blower Policy for employees and/ or volunteers of the Company. The said Policy encourages to report any action or suspected action taken within the Company that is illegal, fraudulent or in violation of any adopted policy of the Company including reporting of instances of leak or suspected leak of unpublished price sensitive information. The Policy also provides access to the Chairperson of the Audit Committee under certain circumstances. The Whistle Blower Policy is posted on the website of the Company at https://admin.alkemlabs.com/ uploads/Whistle_Blower_Policy_new_5d094b8491.pdf

PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE

The Company has adopted a policy fully in compliance with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder.

Internal Complaints Committees have been set up at the head office of the Company as well as at all the Company's plants, depots and R&D centers to redress complaints received on sexual harassment. The details of complaints received during financial year 2025-26 are as under: a. number of complaints of sexual harassment received in the year: 2

b. number of complaints disposed off during the year: 2

c. number of cases pending for more than ninety days : Nil

DISCLOSURES UNDER THE ACT

Change in Nature of Business, if any:

During financial year 2025-26, there has been no change in the nature of business of the Company.

Material Changes and Commitments affecting the financial position of the Company:

There are no material changes and commitments, which have occurred between the end of financial year and the date of the Report which have affected the financial position of the Company.

Significant and Material Orders:

The Company has not received any significant or material orders passed by any regulatory authority, court or tribunal which may impact the going concern status and Company's operations in future.

Reporting of Frauds by Auditors:

During the year under review, there were no frauds reported by Auditors under Section 143(12) of the Act.

Details on Insolvency and Bankruptcy Code:

During the year under review, no application has been made by the Company under the Insolvency and Bankruptcy Code and accordingly the requirement of disclosing the following details are not applicable to the Company:

(i) the details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year alongwith their status as at the end of the financial year; and

(ii) the details of difference between amount of the valuation done at the time of onetime settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof.

DETAILS ON INTERNAL FINANCIAL CONTROLS RELATED TO FINANCIAL STATEMENTS

The Company has established and implemented a robust, process-driven framework for Internal Financial Controls (IFC) in compliance with the requirements of the Companies Act. The Company's policies, standard operating procedures, and control mechanisms are designed to ensure appropriate checks and balances, thereby enabling that all transactions are duly authorised, accurately recorded, and properly reported.

During the year under review, the Internal Auditors with external audit consultants evaluated the adequacy and operating effectiveness of the Company's IFC framework.

Based on their assessment, the Board is of the opinion that the Internal Financial Controls were adequate and operating effectively throughout the financial year.

COMPLIANCE TO THE PROVISIONS RELATING TO THE MATERNITY BENEFITS ACT, 1961.

During the year under review, the Company confirms that it has duly complied with the provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the statutory benefits prescribed under the Act. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under Section 134(3)(m) of the Act and the Rules framed thereunder is annexed herewith as Annexure H to this Report.

ACKNOWLEDGEMENT

Your Directors would like to express sincere gratitude to all valuable stakeholders of the Company viz., the Central and State Government Departments, organizations, agencies, our customers, shareholders, dealers, vendors, banks, medical fraternity, patients and other business associates for their excellent support and co-operation extended by them during the financial year under review.

The Board of Directors also places on record its appreciation for the significant contribution made by the employees of the Company through their dedication, hard work and unstinted commitment.

For and on behalf of the Board

Alkem Laboratories Limited

Basudeo N. Singh

Executive Chairman

DIN: 00760310

Mumbai, 28 May, 2026